{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T03:52:45Z","timestamp":1788407565341,"version":"build-2803163510"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T00:00:00Z","timestamp":1746144000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100004564","name":"Ministarstvo Prosvete, Nauke i Tehnolo\u0161kog Razvoja","doi-asserted-by":"publisher","award":["grant no. 175007\/contract No 451-03-65\/2024-03\/20011"],"award-info":[{"award-number":["grant no. 175007\/contract No 451-03-65\/2024-03\/20011"]}],"id":[{"id":"10.13039\/501100004564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1007\/s13318-025-00947-2","type":"journal-article","created":{"date-parts":[[2025,5,2]],"date-time":"2025-05-02T12:32:30Z","timestamp":1746189150000},"page":"273-287","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clinical Pharmacokinetics and Pharmacodynamics of Vadadustat, an Oral Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitor"],"prefix":"10.1007","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1519-8828","authenticated-orcid":false,"given":"Slobodan M.","family":"Jankovi\u0107","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sne\u017eana V.","family":"Jankovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,2]]},"reference":[{"issue":"13","key":"947_CR1","doi-asserted-by":"publisher","first-page":"1365","DOI":"10.1007\/s40265-020-01383-z","volume":"80","author":"A Markham","year":"2020","unstructured":"Markham A. Vadadustat: first approval. Drugs. 2020;80(13):1365\u201371.","journal-title":"Drugs"},{"issue":"9","key":"947_CR2","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1002\/ajh.26644","volume":"97","author":"MJ Koury","year":"2022","unstructured":"Koury MJ, Agarwal R, Chertow GM, et al. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease. Am J Hematol. 2022;97(9):1178\u201388.","journal-title":"Am J Hematol"},{"key":"947_CR3","unstructured":"PubChem. Vadadustat. Available from: https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/23634441"},{"issue":"6","key":"947_CR4","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1053\/j.ajkd.2016.12.011","volume":"69","author":"N Gupta","year":"2017","unstructured":"Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: a potential new treatment for anemia in patients with CKD. Am J Kidney Dis. 2017;69(6):815\u201326.","journal-title":"Am J Kidney Dis"},{"key":"947_CR5","unstructured":"AJMC. 2024. FDA approves vadadustat for anemia in patients with CKD undergoing dialysis. Available from: https:\/\/www.ajmc.com\/view\/fda-approves-vadadustat-for-anemia-in-patients-with-ckd-undergoing-dialysis."},{"issue":"5","key":"947_CR6","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1016\/S0197-2456(99)00026-4","volume":"20","author":"HD Clark","year":"1999","unstructured":"Clark HD, Wells GA, Hu\u00ebt C, et al. Assessing the quality of randomized trials: reliability of the Jadad scale. Control Clin Trials. 1999;20(5):448\u201352.","journal-title":"Control Clin Trials"},{"key":"947_CR7","unstructured":"SIGN. Checklists. Available from: https:\/\/testing36.scot.nhs.uk."},{"issue":"4","key":"947_CR8","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1002\/cpt.3342","volume":"116","author":"P Navarro-Gonzales","year":"2024","unstructured":"Navarro-Gonzales P, Ganz T, Pergola PE, et al. Pharmacokinetics, pharmacodynamics, and safety of vadadustat in healthy volunteers and patients with chronic kidney disease. Clin Pharmacol Ther. 2024;116(4):1052\u201361.","journal-title":"Clin Pharmacol Ther"},{"key":"947_CR9","unstructured":"Chandorkar GS, Han D, Scmelzer K et al. Pharmacokinetics, pharmacodynamics, and safety of single and multiple oral doses of vadadustat in healthy Japanese and Caucasian subjects. In American Society for Nephrology Annual Meeting; 2016. p. SA-PO506."},{"key":"947_CR10","unstructured":"NDA Executive Summary of the vadadustat quality review No 215192Orig1s000. Center for Drug Evaluation and Research, FDA. 2022. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2024\/215192Orig1s000ChemR.pdf."},{"issue":"8","key":"947_CR11","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1002\/cpdd.927","volume":"10","author":"A Chavan","year":"2021","unstructured":"Chavan A, Burke L, Sawant R, et al. Effect of moderate hepatic impairment on the pharmacokinetics of vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. Clin Pharmacol Drug Dev 2021;10(8):950\u20138.","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"947_CR12","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1007\/s10157-023-02432-z","volume":"28","author":"M Nangaku","year":"2024","unstructured":"Nangaku M, Ueta K, Nishimura K, et al. Factors affecting responsiveness of vadadustat in patients with anemia associated with chronic kidney disease: a post-hoc subgroup analysis of Japanese phase 3 randomized studies. Clin Exp Nephrol. 2024;28(5):391\u2013403.","journal-title":"Clin Exp Nephrol"},{"issue":"Suppl 2","key":"947_CR13","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1093\/ndt\/11.supp2.108","volume":"11","author":"A Gutierrez","year":"1996","unstructured":"Gutierrez A. Protein catabolism in maintenance haemodialysis: the influence of the dialysis membrane. Nephrol Dial Transplant. 1996;11(Suppl 2):108\u201311.","journal-title":"Nephrol Dial Transplant"},{"issue":"8","key":"947_CR14","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1093\/ndt\/5.8.594","volume":"5","author":"FC Fervenza","year":"1990","unstructured":"Fervenza FC, Meredith D, Ellory JC, Hendry BM. A study of the membrane transport of aminoacids in erythrocytes from patients on haemodialysis. Nephrol Dial Transplant. 1990;5(8):594\u20139.","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"947_CR15","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1159\/000126922","volume":"26","author":"E Costa","year":"2008","unstructured":"Costa E, Rocha S, Rocha-Pereira P, et al. Altered erythrocyte membrane protein composition in chronic kidney disease stage 5 patients under haemodialysis and recombinant human erythropoietin therapy. Blood Purif. 2008;26(3):267\u201373.","journal-title":"Blood Purif"},{"issue":"11","key":"947_CR16","doi-asserted-by":"publisher","first-page":"7651","DOI":"10.1039\/C7SC02103H","volume":"8","author":"TL Yeh","year":"2017","unstructured":"Yeh TL, Leissing TM, Abboud MI, et al. Molecular and cellular mechanisms of HIF prolyl hydroxylase inhibitors in clinical trials. Chem Sci. 2017;8(11):7651\u201368.","journal-title":"Chem Sci"},{"issue":"3","key":"947_CR17","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1159\/000455166","volume":"45","author":"F Locatelli","year":"2017","unstructured":"Locatelli F, Fishbane S, Block GA, Macdougall IC. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol. 2017;45(3):187\u201399.","journal-title":"Am J Nephrol"},{"issue":"1","key":"947_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1124\/jpet.122.001126","volume":"383","author":"A Zuk","year":"2022","unstructured":"Zuk A, Si Z, Loi S, et al. Preclinical characterization of vadadustat (AKB-6548), an oral small molecule hypoxia-inducible factor prolyl-4-hydroxylase inhibitor, for the potential treatment of renal anemia. J Pharmacol Exp Ther. 2022;383(1):11\u201324.","journal-title":"J Pharmacol Exp Ther"},{"issue":"4","key":"947_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1053\/j.ackd.2019.04.004","volume":"26","author":"NS Sanghani","year":"2019","unstructured":"Sanghani NS, Haase VH. Hypoxia-inducible factor activators in renal anemia: current clinical experience. Adv Chronic Kidney Dis. 2019;26(4):253\u201366.","journal-title":"Adv Chronic Kidney Dis"},{"issue":"5","key":"947_CR20","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000464476","volume":"45","author":"ER Martin","year":"2017","unstructured":"Martin ER, Smith MT, Maroni BJ, et al. Clinical trial of vadadustat in patients with anemia secondary to stage 3 or 4 chronic kidney disease. Am J Nephrol. 2017;45(5):380\u20138.","journal-title":"Am J Nephrol"},{"issue":"5","key":"947_CR21","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/j.kint.2016.07.019","volume":"90","author":"PE Pergola","year":"2016","unstructured":"Pergola PE, Spinowitz BS, Hartman CS, et al. Vadadustat, a novel oral HIF stabilizer, provides effective anemia treatment in nondialysis-dependent chronic kidney disease. Kidney Int. 2016;90(5):1115\u201322.","journal-title":"Kidney Int"},{"issue":"1","key":"947_CR22","first-page":"90","volume":"34","author":"VH Haase","year":"2019","unstructured":"Haase VH, Chertow GM, Block GA, et al. Effects of vadadustat on hemoglobin concentrations in patients receiving hemodialysis previously treated with erythropoiesis-stimulating agents. Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc. 2019;34(1):90\u20139.","journal-title":"Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc Eur Ren Assoc."},{"key":"947_CR23","doi-asserted-by":"crossref","unstructured":"Nangaku M, Farag YMK, deGoma E, et al. Vadadustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for treatment of anemia of chronic kidney disease: two randomized Phase 2 trials in Japanese patients. Nephrol Dial Transplant. 2020; gfaa060.","DOI":"10.1093\/ndt\/gfaa060"},{"issue":"7","key":"947_CR24","doi-asserted-by":"publisher","first-page":"1779","DOI":"10.1681\/ASN.2020091311","volume":"32","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Kokado Y, et al. Phase 3 randomized study comparing vadadustat with darbepoetin alfa for anemia in Japanese patients with nondialysis-dependent CKD. J Am Soc Nephrol JASN. 2021;32(7):1779\u201390.","journal-title":"J Am Soc Nephrol JASN."},{"issue":"9","key":"947_CR25","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1093\/ndt\/gfab055","volume":"36","author":"M Nangaku","year":"2021","unstructured":"Nangaku M, Kondo K, Ueta K, et al. Efficacy and safety of vadadustat compared with darbepoetin alfa in Japanese anemic patients on hemodialysis: a Phase 3, multicenter, randomized, double-blind study. Nephrol Dial Transplant. 2021;36(9):1731\u201341.","journal-title":"Nephrol Dial Transplant"},{"issue":"17","key":"947_CR26","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1056\/NEJMoa2035938","volume":"384","author":"GM Chertow","year":"2021","unstructured":"Chertow GM, Pergola PE, Farag YMK, et al. Vadadustat in patients with anemia and non-dialysis-dependent CKD. N Engl J Med. 2021;384(17):1589\u2013600.","journal-title":"N Engl J Med"},{"issue":"17","key":"947_CR27","doi-asserted-by":"publisher","first-page":"1601","DOI":"10.1056\/NEJMoa2025956","volume":"384","author":"KU Eckardt","year":"2021","unstructured":"Eckardt KU, Agarwal R, Aswad A, et al. Safety and efficacy of vadadustat for anemia in patients undergoing dialysis. N Engl J Med. 2021;384(17):1601\u201312.","journal-title":"N Engl J Med"},{"key":"947_CR28","doi-asserted-by":"publisher","DOI":"10.34067\/KID.0000000567","author":"L Kooienga","year":"2024","unstructured":"Kooienga L, Burke S, Kathresal A, et al. Safety and efficacy of vadadustat once-daily and 3-times-weekly in dialysis-dependent chronic kidney disease patients with anemia. Kidney. 2024. https:\/\/doi.org\/10.34067\/KID.0000000567.","journal-title":"Kidney"},{"issue":"4","key":"947_CR29","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1053\/j.ajkd.2024.09.006","volume":"85","author":"HR Toka","year":"2025","unstructured":"Toka HR, Bernardo M, Burke SK, et al. Vadadustat three times weekly in patients with anemia due to dialysis-dependent CKD. Am J Kidney Dis. 2025;85(4):454\u201364.","journal-title":"Am J Kidney Dis"},{"key":"947_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.795214","volume":"12","author":"L Xiong","year":"2021","unstructured":"Xiong L, Zhang H, Guo Y, et al. Efficacy and safety of vadadustat for anemia in patients with chronic kidney disease: a systematic review and meta-analysis. Front Pharmacol. 2021;12: 795214.","journal-title":"Front Pharmacol"},{"issue":"4","key":"947_CR31","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/cpdd.1033","volume":"11","author":"SK Paulson","year":"2022","unstructured":"Paulson SK, Martinez J, Sawant R, et al. Effect of phosphate binders and a dietary iron supplement on the pharmacokinetics of a single dose of vadadustat in healthy adults. Clin Pharmacol Drug Dev. 2022;11(4):475\u201385.","journal-title":"Clin Pharmacol Drug Dev."},{"issue":"8","key":"947_CR32","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1016\/j.clinthera.2021.06.013","volume":"43","author":"Y Kokado","year":"2021","unstructured":"Kokado Y, Kawai K, Nanjo T, et al. In vitro and clinical pharmacokinetic studies of the effects of iron-containing agents on vadadustat, an oral hypoxia-inducible factor-prolyl hydroxylase inhibitor. Clin Ther. 2021;43(8):1408-1418.e5.","journal-title":"Clin Ther"},{"key":"947_CR33","unstructured":"Sawant R, Paulson S, Burke L, et al. Effect of food intake on the pharmacokinetics of vadadustat following single dose administration. national kidney foundation 2020 spring clinical meetings. In Los Angeles, USA; 2020. Available from: https:\/\/ir.akebia.com\/static-files\/9b2e9608-6077-4d0e-b112-0a54ead5adc1."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13318-025-00947-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-025-00947-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,4]],"date-time":"2025-07-04T07:25:01Z","timestamp":1751613901000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13318-025-00947-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,2]]},"references-count":33,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["947"],"URL":"https:\/\/doi.org\/10.1007\/s13318-025-00947-2","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,2]]},"assertion":[{"value":"15 April 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Partial financial support was received from the Ministry of Education, Science and Technological Development, Serbia, via grant no. 175007\/contract no. 451-03-65\/2024-03\/20011.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"The authors certify that they have no other relevant affiliations or financial involvement with any organization or entity with a financial interest or nonfinancial interest in the subject matter or materials discussed in this manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable for review article.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable for review article.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable for review article.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable for review article.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material (Data Transparency)"}},{"value":"Not applicable for review article.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability (Software Application or Custom Code)"}},{"value":"Slobodan Jankovi\u0107\u2014concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, and control of completed manuscript. Sne\u017eana Jankovi\u0107\u2014concept of the review, literature search, quality assessment of retrieved articles, writing the manuscript, and control of completed manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}